UNSPSC 51314376: Pheniramine/phenyltoloxamine/pyrilamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AH109. This VA Drug Class (AH109) classifies this compound as belonging to the group ANTIHISTAMINES, OTHER.

UNSPSC 51314376 Pheniramine/phenyltoloxamine/pyrilamine is a Commodity code that in practice covers a much broader spectrum of pharmaceutical procurement than its nominal scope suggests — state and local governments are using it to tag solicitations for naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances administering contracts on behalf of dozens of member jurisdictions. Work under the code ranges from emergency response inventory (naloxone and drug deactivation systems for community health initiatives) to statewide generic pharmaceutical contracting serving state agencies, local facilities, and participating municipalities across multiple states.

Recent activity concentrates in Florida and the upper Midwest, with the most visible current opportunities being Seminole County, Florida's IFB 60459723LAS for naloxone and safe drug deactivation systems (1,900 units of naloxone and 800 deactivation systems annually, response due July 26, 2023), the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products serving Minnesota, Oregon, and member jurisdictions (proposals due March 26, 2026, with contract term effective July 1, 2026), and the Texas Health and Human Services Commission's RFI HHS0017013 exploring direct-to-manufacturer prescription fulfillment models (posted April 3, 2026). The code shows modest recent activity; these three opportunities represent the primary visible solicitations in the most-recent block, and the mismatch between the code's chemical specificity and the pharmaceutical breadth of actual solicitations suggests that state and local buyers are using this code as a catch-all for pharmaceutical procurement rather than restricting it to the named active ingredients.